MMA not harming patients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 12
Volume 16
Issue 12

Cancer patients receiving chemotherapy have not noticed a restriction in their access to treatment following the enactment of the Medicare Prescription Drug Improvement and Modernization Act of 2003

Cancer patients receiving chemotherapy have not noticed a restriction in their access to treatment following the enactment of the Medicare Prescription Drug Improvement and Modernization Act of 2003 (MMA), despite the act's significant reduction in government reimbursement to oncologists, according to a new study from the Duke Clinical Research Institute (Cancer 110:2304-2312, 2007).

The researchers examined results of 1,421 surveys completed via the Internet by 684 patients who had received chemotherapy prior to MMA enactment and 737 who were treated afterward.

"The majority of patients in each group reported being either satisfied or very satisfied with the care they received from their oncologists," said senior investigator Kevin Schulman, MD, director of the DCRI's Center for Clinical and Genetic Economics.

Further, there was no difference in the amount of time from diagnosis to treatment or in average travel time.

"When the act was passed, many were concerned about the consolidation of services it might necessitate, such as the moving of chemotherapy services to hospital rather than outpatient settings and the elimination of staff positions," said lead author Joelle Friedman, a DCRI researcher. "They were afraid these changes would affect patients' access to care, but our study showed these concerns turned out to be largely unwarranted."

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
2 experts in this video
Related Content